Search

Your search keyword '"Moses, Allon E."' showing total 332 results
Start Over Author "Moses, Allon E."
332 results on '"Moses, Allon E."'

1. Successful Treatment of Antibiotic-resistant, Poly-microbial Bone Infection With Bacteriophages and Antibiotics Combination

Author

Nir-Paz, Ran, Gelman, Daniel, Khouri, Ayman, Sisson, Brittany M., Fackler, Joseph, Alkalay-Oren, Sivan, Khalifa, Leron, Rimon, Amit, Yerushalmy, Ortal, Bader, Reem, Amit, Sharon, Coppenhagen-Glazer, Shunit, Henry, Matthew, Quinones, Javier, Malagon, Francisco, Biswas, Biswajit, Moses, Allon E., Merril, Greg, Schooley, Robert T., Brownstein, Michael J., Weil, Yoram A., and Hazan, Ronen

Published
2019

22. Therapeutic Potential of Injectable Nano-Mupirocin Liposomes for Infections Involving Multidrug-Resistant Bacteria

Author

Cern, Ahuva, primary, Bavli, Yaelle, additional, Hod, Atara, additional, Zilbersheid, Daniel, additional, Mushtaq, Shazad, additional, Michael-Gayego, Ayelet, additional, Barasch, Dinorah, additional, Feinstein Rotkopf, Yael, additional, Moses, Allon E., additional, Livermore, David M., additional, and Barenholz, Yechezkel, additional

Published
2021
Full Text
View/download PDF

29. Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010

Author

Averbuch, Diana, Hidalgo-Grass, Carlos, Moses, Allon E., Engelhard, Dan, and Nir-Paz, Ran

Subjects
Care and treatment, Development and progression, Microbial drug resistance -- Development and progression -- Care and treatment, Pneumonia -- Development and progression -- Care and treatment, Bacterial pneumonia -- Development and progression -- Care and treatment, Drug resistance in microorganisms -- Development and progression -- Care and treatment
Abstract

Mycoplasma pneumoniae is a leading respiratory pathogen in both pediatric (1,2) and adult (1,3) populations. Macrolides are considered the first line of therapy and are almost the only treatment for [...]

Published
2011
Full Text
View/download PDF

30. Group G Streptococcal bacteremia in Jerusalem

Author

Cohen-Poradosu, Ronit, Jaffe, Joseph, Lavi, David, Grisariu-Greenzaid, Sigal, Nir-Paz, Ran, Valinsky, Lea, Dan-Goor, Mary, Block, Colin, Beall, Bernard, and Moses, Allon E.

Subjects
Research, Streptococcus -- Research
Abstract

Group G Streptococcus (GGS) can cause severe infections, including bacteremia. These organisms often express a surface protein homologous to the Streptococcus pyogenes M protein. We retrospectively studied the characteristics of [...]

Published
2004

33. Invasive group A streptococcal infections, Israel. (Research)

Author

Moses, Allon E., Goldberg, Sara, Korenman, Zinaida, Ravins, Miriam, Hanski, Emanuel, and Shapiro, Mervyn

Subjects
Jerusalem, Israel -- Health aspects, Research, Health aspects, Population biology -- Research -- Health aspects, Communicable diseases -- Research, Jewish sects -- Health aspects -- Research, Streptococcus pyogenes -- Research -- Health aspects
Abstract

We conducted a prospective, nationwide, population-based study of invasive group A streptococcal infections in Israel. We identified 409 patients (median age 27 years; range ********** Group A streptococcus (GAS) causes [...]

Published
2002

41. Mycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016

Author

Beeton, Michael L., Zhang, Xu-Sheng, Uldum, Soren A., Bebear, Cecile, Dumke, Roger, Gullsby, Karolina, Ieven, Margaretha, Loens, Katherine, Nir-Paz, Ran, Pereyre, Sabine, Spiller, O. Brad, Chalker, Victoria J., Bossuyt, Nathalie, Lagrou, Katrien, Mitis, George, Koliou, Maria, Havlickova, Martina, Kyncl, Jan, Emborg, Hanne-Dorthe, Voldstedlund, Marianne, MacKenzie, Colin Rae, Maltezou, Helena C., Georgakopoulou, Theano, Petridou, Evangelina, Banou, Kirkira, Balla, Eszter, Connell, Jeff, Yandle, Zoe, Moran, Joanne, Burns, Karen, Michael-Gayego, Ayelet, Moses, Allon E., Fenech, Tanya Melillo, Anestad, Gabriel, Blystad, Hans, Vestrheim, Didrik F., Froes, Filipe, Kese, Darja, Socan, Maja, Cano Portero, Rosa, Santos Sanz, Sara, Suarez Rodriguez, Berta, Ternhag, Anders, Giske, Christian, Wisell, Karin Tegmark, Marques, Diogo Pereira, Reynolds, Arlene, McMenamin, Jim, ESCMID Study Grp Mycoplasma Ch, Cardiff Metropolitan University, Public Health England, Statens seruminstitut, Technische Universität Dresden = Dresden University of Technology (TU Dresden), Uppsala University, Antwerp University Hospital [Edegem] (UZA), Hadassah Hebrew University Medical Center, Partenaires INRAE, USC IHMC - Infections humaines à mycoplasmes et à chlamydiae, Institut National de la Recherche Agronomique (INRA), and Cardiff University

Subjects
0301 basic medicine, Mycoplasma pneumoniae, Epidemiology, [SDV]Life Sciences [q-bio], Infektionsmedicin, VARIANTS, medicine.disease_cause, 0302 clinical medicine, Surveys and Questionnaires, diagnostics, Medicine, 030212 general & internal medicine, REAL-TIME PCR, Israel, Diagnostics, Surveillance, Electronic Mail, MACROLIDE RESISTANCE, Mycoplasma pneumoniae Infections, ABSENCE, 3. Good health, Anti-Bacterial Agents, Community-Acquired Infections, Europe, Infectious Diseases, surveillance, GERMANY, epidemiology, Female, Macrolides, Life Sciences & Biomedicine, Nucleic Acid Amplification Techniques, medicine.medical_specialty, Infectious Medicine, 030106 microbiology, FRANCE, Microbiology, 03 medical and health sciences, Age Distribution, EPIDEMIC, Virology, Drug Resistance, Bacterial, Pneumonia, Mycoplasma, Humans, Epidemics, Retrospective Studies, Science & Technology, business.industry, Research, STRAINS, Public Health, Environmental and Occupational Health, medicine.disease, Pneumonia, ANTIBODIES, Human medicine, business
Abstract

Mycoplasma pneumoniae is a major cause of respiratory infection in humans and macrolide antibiotics, such as azithromycin, are used as the first-line of treatment in many countries. The bacterium is transmitted from person-to-person by respiratory droplets with the incubation period ranging from 4 days to 3 weeks [1]. Because of M. pneumoniae’s intrinsic resistance to many antibiotics, including all cell wall inhibitors, macrolide antibiotics such as azithromycin and clarithromycin are the drug of choice for treatment. In cases of suspected infection in immunocompromised individuals, bactericidal fluoroquinolones may be considered. Tetracyclines are an alternative for treatment of adults with possible macrolide-resistant M. pneumoniae infections. Prudent use of antibiotics has been urged for all cases of M. pneumoniae infection because of worldwide reports of macrolide resistance, which have been reported as ranging from 0.2% in Sweden to more than 90% in China [2-5].\ud \ud M. pneumoniae infections show seasonal variation. In temperate climates, the number of infections peak during the latter months of the years, with epidemic periods every 4 to 7 years on average [6-8]. The most recent survey in 2012 by Lenglet et al indicated that some countries in the European Union and European Economic Area experienced an increase in M. pneumoniae cases in 2011 whereas others did not, indicating that a universal geographic increase had not occurred [5]. Little is understood about the transmission of M. pneumoniae within populations and several factors have been postulated to account for transmission dynamics, including the immunity level of the population, the bacterial population based on the P1 adhesin type, the age and extent of mixing of children in educational settings.\ud \ud Methodologies for detection of M. pneumoniae include nucleic acid amplification tests (NAAT), serology and culture with varying sensitivities and specificities. There is no international standard material for quality control detection in assays, although external quality control schema exist for some methodologies (NAAT). There are no internationally defined guidelines on the requirements for surveillance of M. pneumoniae, macrolide resistance testing and surveillance, reference system structure, routine testing and bacterial strain discrimination. However, a few countries such as France and the United States (US) have surveillance within specific regions and national surveillance is seen in countries such as Denmark [9] and Japan, the latter of which has maintained an active surveillance system for this pathogen for some time [10]. Overall, laboratory confirmed cases and surveillance data regarding the number of cases and reported cases of macrolide resistance are likely to be underestimated. This is further confounded because an undefined proportion of patients will have mild disease or may be carriers within community settings, without active testing to confirm the infection. Further underestimation is likely to occur from patients receiving empirical treatment in the absence of laboratory-confirmed infection with M. pneumoniae.

Published
2020
Full Text
View/download PDF

49. Imported melioidosis, Israel, 2008

Author

Cahn, Avivit, Koslowsky, Benjamin, Nir-Paz, Ran, Temper, Violeta, Hiller, Nurit, Karlinsky, Alla, Gur, Itzhak, Hidalgo-Grass, Carlos, Heyman, Samuel N., Moses, Allon E., and Block, Colin

Subjects
Health aspects, Pseudomonas infections -- Health aspects, Diabetes mellitus -- Health aspects, Infection -- Health aspects, Diabetes -- Health aspects
Abstract

Melioidosis, which is caused by Burkholderia pseudomallei, is endemic to some areas of Southeast Asia and northern Australia (1,2). Recent data indicate that it is now endemic to most of [...]

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results